Media

Vicore to Present at Upcoming Investor Conferences

Oncopeptides publishes disclosure document regarding rights issue

Oncopeptides enters into additional guarantee commitments, rights issue fully guaranteed

Positrigo – First University Medical Center in Germany to receive the NeuroLF® system

Oncopeptides carries out rights issue of approximately SEK 150 million and provides update regarding the potential partnership in Japan 

Oncopeptides publishes Q2 report 2025

Intervacc’s distribution partner Dechra launches Strangvac in Spain, Portugal and Slovenia

Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)

Oncopeptides – Invitation to presentation of the Q2 report 2025